Communicable diseases intelligence quarterly report · 2015
Supplemental use of an interferon-gamma release assay in a state-wide tuberculosis contact tracing program in Victoria: a six-year review.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goebel Karen M, Tay Ee L, Denholm Justin T
Аннотация
INTRODUCTION: Tuberculin skin testing (TST) has been the accepted Australian standard for investigating contacts following exposure to infectious tuberculosis (TB). In recent years, the availability of the interferon-gamma release assays (IGRA) has introduced a potential alternative test but data on its use in this context are limited.
METHODS: A prospective longitudinal cohort study was conducted from 2008-2013 to review the use of IGRA and subsequent TB disease following testing in a state-wide contact tracing program. Additional information on the experience and acceptability of IGRA in this context was also obtained through program staff surveys following implementation.
RESULTS: IGRA testing was performed on 643 contacts, with a mean follow-up of 3.7 years. IGRA was primarily used to supplement TST, most commonly due to borderline TST reactivity in individuals who had bacille Calmette-Guérin vaccination. Where both TST and IGRA were performed, correlation of test results was poor (kappa=0.35). The negative predictive value for later development of active TB was 99.5%.
CONCLUSIONS: Our experience suggests that IGRA are able to be incorporated safely and effectively as a supplement to TST-based contact tracing.
METHODS: A prospective longitudinal cohort study was conducted from 2008-2013 to review the use of IGRA and subsequent TB disease following testing in a state-wide contact tracing program. Additional information on the experience and acceptability of IGRA in this context was also obtained through program staff surveys following implementation.
RESULTS: IGRA testing was performed on 643 contacts, with a mean follow-up of 3.7 years. IGRA was primarily used to supplement TST, most commonly due to borderline TST reactivity in individuals who had bacille Calmette-Guérin vaccination. Where both TST and IGRA were performed, correlation of test results was poor (kappa=0.35). The negative predictive value for later development of active TB was 99.5%.
CONCLUSIONS: Our experience suggests that IGRA are able to be incorporated safely and effectively as a supplement to TST-based contact tracing.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overBCG VaccineChildChild, PreschoolContact TracingDisease NotificationFemaleHumansInfantInfant, NewbornInterferon-gamma Release TestsLongitudinal StudiesMaleMiddle AgedNational Health ProgramsProspective StudiesSensitivity and SpecificityTuberculin TestTuberculosisVictoriaYoung Adult